JP2007500217A - 同種異系細胞治療：ミラー効果 - Google Patents

同種異系細胞治療：ミラー効果 Download PDF

Info

Publication number
JP2007500217A
JP2007500217A JP2006532922A JP2006532922A JP2007500217A JP 2007500217 A JP2007500217 A JP 2007500217A JP 2006532922 A JP2006532922 A JP 2006532922A JP 2006532922 A JP2006532922 A JP 2006532922A JP 2007500217 A JP2007500217 A JP 2007500217A
Authority
JP
Japan
Prior art keywords
cells
allogeneic
host
tumor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500217A5 (enExample
Inventor
マイケル ハル−ノイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33425748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007500217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of JP2007500217A publication Critical patent/JP2007500217A/ja
Publication of JP2007500217A5 publication Critical patent/JP2007500217A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2006532922A 2003-05-13 2004-05-11 同種異系細胞治療：ミラー効果 Pending JP2007500217A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47017103P 2003-05-13 2003-05-13
US54545004P 2004-02-18 2004-02-18
US54796604P 2004-02-26 2004-02-26
US54903204P 2004-03-01 2004-03-01
US10/838,454 US7435592B2 (en) 2003-05-13 2004-05-04 Compositions for allogeneic cell therapy
PCT/US2004/014589 WO2005001074A1 (en) 2003-05-13 2004-05-11 Allogeneic cell therapy: mirror effect

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010232031A Division JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果

Publications (2)

Publication Number Publication Date
JP2007500217A true JP2007500217A (ja) 2007-01-11
JP2007500217A5 JP2007500217A5 (enExample) 2010-12-02

Family

ID=33425748

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006532922A Pending JP2007500217A (ja) 2003-05-13 2004-05-11 同種異系細胞治療：ミラー効果
JP2010232031A Expired - Lifetime JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果
JP2011157205A Withdrawn JP2011225602A (ja) 2003-05-13 2011-07-15 同種異系細胞治療：ミラー効果
JP2014207763A Withdrawn JP2015028072A (ja) 2003-05-13 2014-10-09 同種異系細胞治療：ミラー効果
JP2016152801A Pending JP2016190868A (ja) 2003-05-13 2016-08-03 同種異系細胞治療：ミラー効果

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010232031A Expired - Lifetime JP6030819B2 (ja) 2003-05-13 2010-10-14 同種異系細胞治療：ミラー効果
JP2011157205A Withdrawn JP2011225602A (ja) 2003-05-13 2011-07-15 同種異系細胞治療：ミラー効果
JP2014207763A Withdrawn JP2015028072A (ja) 2003-05-13 2014-10-09 同種異系細胞治療：ミラー効果
JP2016152801A Pending JP2016190868A (ja) 2003-05-13 2016-08-03 同種異系細胞治療：ミラー効果

Country Status (6)

Country Link
US (15) US7435592B2 (enExample)
EP (1) EP1627054A1 (enExample)
JP (5) JP2007500217A (enExample)
CA (1) CA2525596C (enExample)
IL (4) IL171850A (enExample)
WO (1) WO2005001074A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
JP2007526314A (ja) * 2004-03-01 2007-09-13 イミュノバティブ セラピーズ， リミテッド 細胞治療処方方法および組成物
JP2011519869A (ja) * 2008-05-02 2011-07-14 イミュノバティブ セラピーズ， リミテッド ワクチン組成物および方法
JP2013514365A (ja) * 2009-12-15 2013-04-25 イミュノバティブ セラピーズ， リミテッド 腫瘍の一掃のための方法および組成物
JP2013523886A (ja) * 2010-04-13 2013-06-17 イミュノバティブ セラピーズ， リミテッド 制御性ｔ細胞の阻害のための方法および組成物
JP2013536232A (ja) * 2010-08-20 2013-09-19 イミュノバティブ セラピーズ， リミテッド Ｔｈ１特性と細胞溶解性を発現する細胞
JP2014513126A (ja) * 2011-05-03 2014-05-29 イミュノバティブ セラピーズ，リミテッド 免疫療法を用いたｉｌ−１２の誘導
JP2014517830A (ja) * 2011-05-03 2014-07-24 イミュノバティブ セラピーズ，リミテッド 生細胞を含む生物学的薬剤の取り扱い方法
JP2018108091A (ja) * 2011-04-08 2018-07-12 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法
JP2022524146A (ja) * 2019-03-08 2022-04-27 ソプ シン，ジ 他家免疫細胞培養方法、その方法により得られた免疫細胞培養液、及びこれを含む免疫細胞治療剤
JP2022528079A (ja) * 2019-03-27 2022-06-08 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) * 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20070025961A1 (en) 2003-06-03 2007-02-01 Kenzo Bamba Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US8865224B2 (en) 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection
GB0622400D0 (en) * 2006-11-10 2006-12-20 Avaris Ab Novel compositions and uses thereof
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US9320794B2 (en) 2006-11-13 2016-04-26 Immunovative Therapies, Ltd. Ablative immunotherapy
US20090232032A1 (en) * 2007-01-17 2009-09-17 Verbal World, Inc. Methods and Apparatus for the Manipulation of Conferenced Data
WO2009100444A1 (en) * 2008-02-08 2009-08-13 Verbal World, Inc. Methods and apparatus for exhange of electronic communications
US9695397B2 (en) * 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
JP5725489B2 (ja) * 2008-06-27 2015-05-27 公立大学法人大阪市立大学 医療用組成物および医療用キット
WO2010059253A2 (en) 2008-11-24 2010-05-27 Massachusets Institute Of Technology Methods and compositions for localized agent delivery
US8415150B2 (en) 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
WO2011140170A1 (en) 2010-05-04 2011-11-10 Yeda Research And Development Co. Ltd. Immunotherapy using redirected allogeneic cells
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
US20130071437A1 (en) * 2010-08-06 2013-03-21 Canine-Lab.Inc. Immunological function enhancing agent
EP2471543A1 (en) * 2010-12-02 2012-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
AU2012205643A1 (en) 2011-01-10 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of allogeneic hematopoietic stem cell transplantation
RU2488356C1 (ru) * 2012-02-28 2013-07-27 Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) Способ коррекции иммунных нарушений
TWI676481B (zh) * 2012-05-02 2019-11-11 以色列商梵提夫免疫療法公司 使用免疫療法誘導ｉｌ－１２
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
CA2782942C (en) * 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
CN102809596B (zh) * 2012-08-21 2014-07-09 辉源生物科技（上海）有限公司 分离培养新生鼠皮层神经细胞记录t型钙通道电流的方法
US20140065096A1 (en) * 2012-09-05 2014-03-06 Regen BioPharma, Inc. Cancer therapy by ex vivo activated autologous immune cells
DK3019176T3 (da) 2013-07-12 2020-06-22 Canadian Blood Services Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf
JP7097667B2 (ja) 2013-09-27 2022-07-08 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体
US10272143B2 (en) 2014-01-08 2019-04-30 Immunovative Therapies Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
US10739353B2 (en) 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
TWI716405B (zh) 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
CN108990413A (zh) 2015-08-12 2018-12-11 麻省理工学院 纳米颗粒的细胞表面偶联
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
WO2019221991A1 (en) * 2018-05-14 2019-11-21 Regents Of The University Of Minnesota Manipulating arid5b expression in immune cells to promote metabolism, survival, and function
EP3834833A4 (en) * 2018-08-10 2022-05-18 Eutilex Co., Ltd. Cancer antigen-specific cytotoxic t cells
WO2020210843A2 (en) * 2019-04-12 2020-10-15 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
IL297279A (en) 2020-04-15 2022-12-01 Alkermes Pharma Ireland Ltd Immunostimulants in combination with blood vessel formation inhibitors
US20250319132A1 (en) * 2024-04-16 2025-10-16 Mirror Biologics, Inc. Methods and compositions for improving the immune response against viral pathogens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672895A (ja) * 1991-04-19 1994-03-15 Tanox Biosyst Inc 免疫調節能を有する物質及び組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
WO1994012196A1 (en) 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
IL107483A0 (en) 1993-11-03 1994-02-27 Yeda Res & Dev Bone marrow transplantation
WO1996037208A1 (en) * 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
WO1997005239A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
CA2254975C (en) 1996-05-23 2008-12-16 The Scripps Research Institute Mhc class ii antigen-presenting systems and methods for activating cd4+ t cells
JP2001522806A (ja) 1997-11-10 2001-11-20 アーチ・デヴェロップメント・コーポレイション エクス・ビボ活性化ｔ細胞を用いる腫瘍および腫瘍細胞の処理方法
ATE439137T1 (de) 1997-11-14 2009-08-15 Gen Hospital Corp Behandlung von hämatologischen störungen
EP1100515B1 (en) 1998-07-30 2005-11-16 Regents Of The University Of Minnesota EX VIVO TREATMENT OF ALLOGENEIC AND XENOGENEIC T-CELLS WITH gp39 ANTAGONISTS
DK1257632T3 (da) 2000-02-24 2008-01-28 Xcyte Therapies Inc Samtidig stimulering og opkoncentrering af celler
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
AU2001292564A1 (en) 2000-08-31 2002-03-13 Emory University A method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease
CA2457143A1 (en) * 2001-08-17 2003-02-27 Roger Williams Hospital In situ immunization
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002342299A1 (en) 2001-10-31 2003-05-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Generation of use of tc1 and tc2 cells
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7678572B2 (en) 2004-02-26 2010-03-16 Immunovative Therapies, Ltd. Methods for preparing T-cells for cell therapy
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
US8865224B2 (en) * 2004-10-14 2014-10-21 Immunovative Therapies Ltd. Allogeneic cellular immunotherapy for opportunistic infection
DK2003978T3 (da) 2006-04-13 2014-07-07 Immunovative Therapies Ltd Allogen celleterapi til behandling af opportunistisk infektion
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672895A (ja) * 1991-04-19 1994-03-15 Tanox Biosyst Inc 免疫調節能を有する物質及び組成物

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
JP2007526314A (ja) * 2004-03-01 2007-09-13 イミュノバティブ セラピーズ， リミテッド 細胞治療処方方法および組成物
JP2011519869A (ja) * 2008-05-02 2011-07-14 イミュノバティブ セラピーズ， リミテッド ワクチン組成物および方法
JP2016121164A (ja) * 2009-12-15 2016-07-07 イミュノバティブ セラピーズ，リミテッド 腫瘍の一掃のための方法および組成物
JP2013514365A (ja) * 2009-12-15 2013-04-25 イミュノバティブ セラピーズ， リミテッド 腫瘍の一掃のための方法および組成物
JP2018090605A (ja) * 2009-12-15 2018-06-14 イミュノバティブ セラピーズ，リミテッド 腫瘍の一掃のための方法および組成物
JP2013523886A (ja) * 2010-04-13 2013-06-17 イミュノバティブ セラピーズ， リミテッド 制御性ｔ細胞の阻害のための方法および組成物
JP2016155851A (ja) * 2010-04-13 2016-09-01 イミュノバティブ セラピーズ，リミテッド 制御性ｔ細胞の阻害のための方法および組成物
JP2017061558A (ja) * 2010-08-20 2017-03-30 イミュノバティブ セラピーズ，リミテッド Ｔｈ１特性と細胞溶解性を発現する細胞
JP2013536232A (ja) * 2010-08-20 2013-09-19 イミュノバティブ セラピーズ， リミテッド Ｔｈ１特性と細胞溶解性を発現する細胞
US10385315B2 (en) 2010-08-20 2019-08-20 Immunovative Therapies, Ltd. Cells expressing Th1 characteristics and cytolytic properties
JP2018108091A (ja) * 2011-04-08 2018-07-12 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ キメラサイトカイン受容体を用いて、腫瘍微小環境の影響を逆転する方法
JP2014517830A (ja) * 2011-05-03 2014-07-24 イミュノバティブ セラピーズ，リミテッド 生細胞を含む生物学的薬剤の取り扱い方法
JP2014513126A (ja) * 2011-05-03 2014-05-29 イミュノバティブ セラピーズ，リミテッド 免疫療法を用いたｉｌ−１２の誘導
JP2017141287A (ja) * 2011-05-03 2017-08-17 イミュノバティブ セラピーズ，リミテッド 免疫療法を用いたｉｌ−１２の誘導
US11045541B2 (en) 2011-05-03 2021-06-29 Mirror Biologics, Inc. Allogeneic T-cell compositions for induction of IL-12
US11883490B2 (en) 2011-05-03 2024-01-30 Mirror Biologics, Inc. Induction of IL-12 using immunotherapy
JP2022524146A (ja) * 2019-03-08 2022-04-27 ソプ シン，ジ 他家免疫細胞培養方法、その方法により得られた免疫細胞培養液、及びこれを含む免疫細胞治療剤
JP2022528079A (ja) * 2019-03-27 2022-06-08 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物
JP7335971B2 (ja) 2019-03-27 2023-08-30 ソプ シン，ジ Ｎｋ細胞培養培地用添加組成物、前記添加組成物を用いたｎｋ細胞培養方法、及び前記培養方法で得られた皮膚トラブル改善用化粧料組成物

Also Published As

Publication number Publication date
US20130052212A1 (en) 2013-02-28
US20140154278A1 (en) 2014-06-05
US7435592B2 (en) 2008-10-14
US9511127B2 (en) 2016-12-06
IL223010A0 (en) 2012-12-31
US20140294781A1 (en) 2014-10-02
JP2015028072A (ja) 2015-02-12
IL223011A0 (en) 2012-12-31
CA2525596A1 (en) 2005-01-06
US20170360909A1 (en) 2017-12-21
CA2525596C (en) 2017-10-10
US20110206708A1 (en) 2011-08-25
JP2011006491A (ja) 2011-01-13
WO2005001074A1 (en) 2005-01-06
JP6030819B2 (ja) 2016-11-24
US8778678B2 (en) 2014-07-15
IL223009A0 (en) 2012-12-31
EP1627054A1 (en) 2006-02-22
US20140193385A1 (en) 2014-07-10
US20110028912A1 (en) 2011-02-03
US8076135B2 (en) 2011-12-13
US9301977B2 (en) 2016-04-05
US8728534B2 (en) 2014-05-20
US10806777B2 (en) 2020-10-20
US8298587B2 (en) 2012-10-30
JP2011225602A (ja) 2011-11-10
IL223011A (en) 2017-10-31
US8785188B2 (en) 2014-07-22
US9782463B2 (en) 2017-10-10
US9352001B2 (en) 2016-05-31
US20110206707A1 (en) 2011-08-25
IL171850A (en) 2014-02-27
US8354276B2 (en) 2013-01-15
US20100322966A1 (en) 2010-12-23
US20080279861A1 (en) 2008-11-13
US20160158328A1 (en) 2016-06-09
US7943180B2 (en) 2011-05-17
US20110033435A1 (en) 2011-02-10
JP2016190868A (ja) 2016-11-10
US8679841B2 (en) 2014-03-25
US8273377B2 (en) 2012-09-25
US20110040259A1 (en) 2011-02-17
US20080279836A1 (en) 2008-11-13
US20040228848A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
JP6030819B2 (ja) 同種異系細胞治療：ミラー効果
JP2007500217A5 (enExample)
US10385315B2 (en) Cells expressing Th1 characteristics and cytolytic properties
HK1257638A1 (en) Cells expressing th1 characteristics and cytolytic properties
HK1184498A (en) Cells expressing th1 characteristics and cytolytic properties

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100715

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100806

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329